deminer
bone
matrix
dbm
osteoconduct
osteoinduct
commerci
biomateri
approv
medic
devic
use
bone
defect
long
track
record
clinic
use
divers
form
true
name
acidextract
organ
matrix
human
bone
sourc
dbm
retain
much
proteinac
compon
nativ
bone
small
amount
calciumbas
solid
inorgan
phosphat
trace
cell
debri
mani
dbm
proteinac
compon
eg
growth
factor
known
potent
osteogen
agent
commerci
sourc
putti
past
sheet
flexibl
piec
dbm
provid
degrad
matrix
facilit
endogen
releas
compound
bone
wound
site
surgic
place
fill
bone
defect
induc
new
bone
format
acceler
heal
given
dbm
long
clinic
track
record
commerci
access
standard
form
sourc
opportun
develop
valid
dbm
versatil
bone
biomateri
orthoped
repair
regen
medicin
context
attract
deminer
bone
matrix
dbm
import
therapeut
option
appendicular
axial
craniofaci
skeleton
skelet
local
dbm
osteoconduct
osteoinduct
properti
prompt
bone
regener
consequ
procedur
per
year
per
year
bone
graft
market
focus
use
dbm
product
bone
repair
regen
strategi
unit
state
food
drug
agenc
fda
approv
recombin
human
bone
morphogenet
infus
tm
medtronicsofamordanek
recombin
human
plateletderiv
growth
factorbb
rhpdgfbb
tm
biomimet
therapeut
inc
purifi
therapeut
agent
bone
repair
significantli
decreas
either
clinic
corpor
enthusiasm
clinic
need
dbm
product
clinic
enthusiasm
dbm
underscor
quantiti
research
clinic
public
regard
use
search
pubm
databas
public
mention
deminer
bone
titl
abstract
past
reveal
sustain
continu
number
dbm
public
fig
robust
clinic
demand
dbm
human
patient
tissu
bank
compani
continu
commit
remark
resourc
produc
divers
array
dbmcontain
productsto
point
clinician
often
confus
dbm
product
divers
moreov
uncertainti
exist
clinic
valid
variou
claim
made
commerci
vendor
dbmcontain
product
addit
combin
dbm
biomateri
sever
composit
form
increas
versatil
clinic
human
tissuederiv
product
expand
capabl
bone
repair
sever
factor
regard
dbm
humanderiv
tissu
product
import
understand
guid
use
bone
repair
matrix
vehicl
deliv
bioactiv
agent
exampl
bone
procur
techniqu
human
donor
donor
age
gender
dbm
composit
properti
differ
prepar
process
method
bone
impact
properti
clinic
perform
biolog
test
process
bone
outcom
measur
valid
biolog
activ
ie
socal
osteoinduct
index
oi
describ
herein
uniform
among
tissu
bank
result
dbm
product
variabl
composit
properti
variabl
obviou
signific
clinician
patient
also
issu
understand
perform
research
studi
addit
dbm
product
consist
bonederiv
particl
size
particl
size
rang
even
protein
fiber
dbm
steril
protocol
also
variabl
final
composit
variou
carrier
combin
dbm
dbm
combin
variou
bioactiv
substanc
influenc
clinic
research
outcom
best
practic
consensu
use
difficult
ascertain
literatur
divers
type
dbm
product
well
commerci
claim
regard
perform
product
lead
mani
question
clinic
effect
futur
opportun
understand
best
use
given
dbm
substanti
histori
weav
biolog
togeth
clinic
applic
initi
review
histori
contemporari
factual
clinic
basi
dbm
properti
clinic
util
bone
repair
use
understand
current
usag
trend
futur
opportun
importantli
context
dbm
origin
sourc
discoveri
sever
key
growth
factor
subsequ
clone
recombinantli
express
becom
fdaapprov
clinic
therapeut
protein
bone
repair
longer
fdaapprov
highli
restrict
human
devic
exempt
label
earli
public
haraka
glowacki
mulliken
provid
key
histor
inform
first
identifi
recogn
import
pioneer
work
dbm
context
dbm
use
prompt
clinic
recognit
valu
bone
graft
alon
substanti
histori
report
regard
russian
soldier
success
treat
dog
bone
graft
first
report
bone
xenograft
elicit
vocifer
condemn
christian
church
treat
surgeon
meekren
fear
excommun
remov
xenograft
autograft
also
report
macewen
specul
transplant
osteoblast
carri
autograft
respons
success
senn
use
decalcifi
bone
treat
osseou
defect
soak
tibia
oxen
hydrochlor
acid
hcl
use
logic
hcl
antisept
effect
xenograft
would
benefit
patient
osteomyel
deaver
curti
macki
valid
senn
work
world
war
combatincur
injuri
requir
bone
graft
prompt
resurg
autograft
notabl
clinicianscientist
phemist
grove
systemat
studi
autograft
use
preclin
model
phemist
underscor
need
mechan
stress
success
structur
bone
graft
concept
load
may
specif
state
implic
limb
function
follow
graft
import
posit
bonepromot
stimulu
phemist
introduc
creep
substitut
concept
host
bone
grow
bulk
allograft
barth
axhausen
previous
describ
process
host
bone
grow
graft
bone
contemporari
nomenclatur
creep
substitut
osteoconduct
term
coin
urist
review
grove
emphas
import
secur
fixat
graft
recipi
bed
well
note
viabl
bone
produc
better
outcom
nonviabl
bone
improv
surgic
skill
patient
care
produc
commensur
decreas
morbid
mortal
follow
bone
autograft
howev
despit
benefit
compel
concern
autograft
invas
donor
procedur
recov
graft
moreov
inadequ
donor
bone
improperli
shape
recipi
site
addit
concern
furthermor
time
oper
room
tabl
infect
risk
increas
patient
care
cost
concern
persist
today
contemporari
challeng
noteworthi
overal
risk
infect
hospit
intern
remain
substanti
consequ
centuri
clinician
sought
altern
autograft
minim
hospit
exposurea
linger
quest
remain
centuri
clinician
well
initi
altern
autograft
offer
huggin
describ
propiti
find
transit
epithelium
urogenit
system
promot
ectop
osteogenesi
format
bone
connect
tissu
site
report
similar
neuhof
observ
fascia
use
augment
bladder
dog
elicit
ectop
osteogen
outcom
interestingli
urist
colleagu
report
detect
messeng
rna
bone
morphogenet
protein
bmp
bladder
tissu
produc
import
causal
connect
import
dbm
develop
report
ectop
osteogenesi
follow
two
provoc
paper
describ
respons
muscl
alcohol
extract
prepar
bone
alcohol
extract
inject
skelet
muscl
produc
osteogenesi
studi
phenomenolog
biolog
explan
offer
lacroix
thought
bone
contain
substanc
enabl
osteogenesi
paper
natur
state
osteogenin
specul
bone
initi
growth
ray
holloway
urist
landmark
paper
scienc
determin
ectop
osteogenesi
occur
deminer
bone
implant
nonboni
site
elegantli
detail
scientif
explan
ectop
osteogenesi
coin
term
autoinduct
urist
posit
substratum
nonminer
matrix
bone
key
provid
morphogenet
signal
prompt
osteogenesi
highli
noteworthi
urist
strate
introduc
bone
morphogenet
protein
bmp
osteoinduct
scientif
clinic
commun
urist
systemat
lucidli
present
visionari
processstil
highli
relev
todayof
bone
morphogenesi
promot
deminer
compon
bone
organ
substratum
urist
call
reddi
clarifi
cellular
molecular
biolog
ectop
osteogenesi
caus
deminer
bone
dentin
matric
reddi
anderson
refin
polish
urist
work
induc
osteogenesi
provid
first
credibl
compel
explan
function
role
purifi
organ
bone
matric
ie
bone
deminer
matrix
sampath
reddi
state
function
collabor
solubl
extract
insolubl
collagen
substratum
ie
deminer
matrix
necessari
optim
osteogen
activ
reddi
loyal
colleagu
identifi
factor
solubl
extract
crucial
ectop
ossif
respect
hallmark
work
lacroix
along
line
reddi
call
one
factor
osteogenin
later
also
identifi
reddi
comprehens
pioneer
work
dbm
enabl
clone
express
recombin
human
bmp
reddi
acknowledg
incis
work
wozney
colleagu
clone
bone
morphogenet
protein
accomplish
follow
cowork
clone
bmp
also
call
osteogen
protein
respect
bmp
molecul
part
solubl
extract
reddi
first
identifi
origin
deminer
bone
matrix
dbm
review
summari
profound
clinic
ramif
solubl
bone
extract
contain
bmp
influenti
bone
growth
promot
substanc
known
dbm
attribut
reddi
discipl
clariti
take
clue
centuri
previou
larg
phenomenolog
work
focus
research
attent
solubl
compon
bone
organ
matrix
deminer
compon
proven
contain
biolog
driver
essenti
osteogenesi
histori
provid
conceptu
foundat
develop
sever
issu
german
biolog
activ
dbm
clinic
util
includ
procur
donor
profil
eg
gender
age
process
product
issu
steril
combin
carrier
biomateri
origin
dbm
clinic
product
human
donor
donor
bone
contemporari
jargon
refer
allograft
howev
remov
bone
donor
well
process
donor
bone
render
tissu
void
viabl
cell
therefor
definit
dbm
product
alloimpl
contain
viabl
cell
contrast
autograft
contain
viabl
cell
procur
process
donor
bone
tissu
becom
dbm
use
term
allograft
despit
fact
bone
allograft
cellfre
matrix
bone
contain
inorgan
organ
matric
consequ
donor
procur
obtain
graft
primari
risk
allograft
bone
product
transmiss
infecti
diseas
donor
recipi
sinc
implement
rigor
product
test
began
ago
rare
isol
instanc
diseas
transmiss
report
may
result
consequ
unscrupul
tissu
bank
procedur
notabl
event
occur
irrespons
group
adher
tissu
procur
guidelin
advoc
american
associ
tissu
bank
aatb
method
prepar
dbm
donor
bone
gener
steril
product
elimin
potenti
infecti
agent
nevertheless
first
line
defens
diseas
transmiss
donor
screen
donor
screen
begin
procur
level
avoid
transmiss
infecti
diseas
potenti
donor
screen
specif
exclusionari
risk
factor
procur
process
highli
regul
fda
specif
requir
found
titl
code
feder
regul
cfr
part
complianc
tissu
process
guidelin
requir
cooper
independ
organ
includ
hospitalbas
medic
staff
recoveri
screen
organ
tissu
process
facil
sale
distribut
organ
start
point
assess
suitabl
donor
conduct
recoveri
screen
organ
base
gener
criteria
follow
initi
medic
screen
famili
deceas
donor
consult
obtain
inform
consent
tissu
donat
triag
consent
step
success
tissu
process
facil
contact
take
respons
final
screen
number
guidanc
document
continu
updat
account
newli
identifi
risk
factor
avail
fda
recommend
screen
potenti
donor
exclusionari
risk
factor
exampl
current
fda
guidanc
document
includ
potenti
exposur
newli
identifi
zoonot
diseas
west
nile
viru
wnv
sever
acut
respiratori
syndrom
sar
exclusionari
risk
factor
fda
mandat
detail
medic
social
histori
obtain
uncov
social
behavior
risk
factor
see
supplementari
tabl
inform
obtain
interview
famili
close
contact
donor
instanc
identif
behavior
risk
factor
disqualifi
donor
case
trigger
investig
next
assess
physic
examin
may
reveal
evid
risk
factor
sign
patholog
otherwis
detect
serolog
test
could
lead
donor
exclus
supplementari
tabl
final
seri
clinic
test
complet
rule
human
immunodefici
viru
hiv
type
hepat
b
viru
hbv
hepat
c
viru
hcv
treponema
pallidum
syphili
human
donor
qualif
process
dbm
sourc
rigor
stringent
intent
ensur
procur
diseasefre
tissu
dbm
biomateri
requisit
safe
efficaci
patient
use
direct
product
donor
allograft
bone
dbm
composit
collagen
mostli
type
type
iv
x
noncollagen
protein
growth
factor
variabl
percent
residu
calcium
phosphat
miner
small
percent
cellular
debri
gener
dbm
prepar
protocol
includ
donor
bone
debrid
adher
soft
tissu
remov
blood
lipid
point
often
antibiot
soak
use
initi
steril
process
subsequ
cleans
donor
bone
morsel
defin
particl
fiber
subject
acid
deminer
follow
one
round
freezedri
miner
phase
extract
particul
whole
donor
bone
n
hcl
leav
organ
matrix
intact
upon
freezedri
result
deminer
bone
powder
synonym
dbm
formul
putti
past
recent
flexibl
preform
strip
implant
use
freezedri
one
step
process
led
altern
dbm
term
deminer
freezedri
bone
allograft
dfdba
biolog
clinic
justif
deminer
donor
bone
yield
dbm
dfdba
provid
dbm
contain
abund
bone
morphogenet
protein
known
essenti
bone
growth
regener
biolog
subsequ
clinic
impact
bone
deminer
dbm
residu
calcium
may
influenc
osteoinduct
honsaek
cowork
suggest
bmp
dbm
mayb
readili
extract
calcium
content
dbm
decreas
howev
bmp
content
dbm
also
suggest
like
less
import
extract
releas
host
implant
site
extent
bone
deminer
constant
dbm
particl
size
remain
morsel
powder
dbm
fiber
geometri
produc
process
bonederiv
collagen
protein
defin
dbm
surfac
area
clinic
variabl
differ
surfac
geometri
may
impact
host
cellular
interact
well
diffus
rate
dbmresid
biolog
molecul
endogen
agent
bmp
growth
factor
dbm
consequ
discuss
regard
optim
size
size
rang
particl
dbm
prepar
suggest
particl
less
osteoinduct
largers
particl
gener
preclin
data
inconsist
regard
dbm
composit
particl
size
rang
well
fiber
dbm
formul
sheet
gel
inconsist
due
differ
anim
model
outcom
measur
mani
highli
subject
uniqu
one
laboratori
univers
accept
moreov
human
data
dbm
weak
due
part
emphasi
dbm
bone
graft
extend
rather
standalon
therapi
consequ
efficaci
differ
formul
dbm
clearli
elucid
formul
design
featur
larg
empir
ascertain
arbitrari
test
bed
addit
concern
regard
possibl
effect
bisphosphon
use
may
dbm
donor
taken
drug
treat
osteoporosi
recent
work
indic
dbm
process
human
donor
known
histori
bisphosphon
use
purifi
free
alendron
elimin
concern
inadvert
dbm
contamin
donor
use
bonebind
drug
address
relat
concern
possibl
pauciti
bioactiv
compon
alendronatetr
bone
result
dbm
boyan
group
found
detect
chang
abil
dbm
human
donor
treat
bisphosphon
induc
bone
format
compar
dbm
howev
determin
new
bone
qualiti
affect
end
product
bone
deminer
process
dbm
powder
may
difficult
manag
clinic
consequ
sever
carrier
use
incorpor
high
mass
fraction
dbm
powder
facilit
handl
formul
reliabl
deliveri
dbm
product
clinic
divers
type
commerci
dbmcarrier
product
known
avail
list
tabl
current
popular
clinic
dbm
format
moldabl
putti
pack
bone
defect
resist
dispers
irrig
blood
surgeri
convers
dbm
powder
putti
involv
formul
biocompat
viscou
carrier
provid
stabl
suspens
dbm
powder
particl
viscou
carrier
classifi
watersolubl
polym
sodium
hyaluron
carboxymethylcellulos
anhydr
watermisc
solvent
glycerol
case
carrier
select
implic
process
step
compat
applic
even
steril
dbm
mix
carrier
produc
flexibl
sheet
may
contain
dbm
cortic
bone
chip
composit
biomateri
addit
polym
carrier
pluron
basf
product
synonym
poloxam
temperaturesensit
biomed
copolym
carrier
use
dbm
composit
becom
firmer
warm
bodi
temperatur
anoth
carrier
thermoplast
porcin
collagenbas
hydrogel
nonwatersolubl
dbmporcin
collagen
extrud
syring
heat
situ
bodi
temperatur
composit
becom
firm
studi
design
discrimin
effect
variou
carrier
dbm
pre
clinic
efficaci
limit
wang
implant
athym
rat
commerci
avail
dbm
dynagraft
putti
grafton
putti
osteofil
allograft
bone
past
spinal
fusion
segment
implant
grafton
osteofil
fuse
none
segment
implant
dynagraft
fuse
sassard
colleagu
report
retrospect
review
patient
undergon
instrument
posterolater
lumbar
spinal
fusion
autogen
bone
graft
grafton
gel
age
gender
procedurematch
group
patient
involv
differ
treatment
group
autograft
vs
autograft
plu
grafton
base
radiograph
surgeri
fusion
rate
autograft
grafton
group
autograftonli
group
respect
import
predictor
bone
miner
correl
type
instrument
fusion
success
bostrom
cowork
implant
grafton
subcutan
athym
rat
report
acut
tubular
necrosi
specul
glycerol
compon
grafton
led
nephrotxo
howev
dose
time
human
clinic
dose
nevertheless
glycerolcontain
product
use
caution
pediatr
patient
risk
renal
diseas
acarturk
holling
determin
preclin
model
orthop
criticals
defect
site
treatment
either
grafton
dbx
promot
significantli
bone
regener
dbmcarrier
product
conclud
differ
osteogen
activ
among
commerci
dbm
product
may
relat
differ
carrier
amount
dbm
carrier
abil
carrier
local
dbm
particul
bone
defect
site
suffici
period
promot
bone
regener
import
variabl
inher
product
dbm
content
among
differ
commerci
composit
ie
dbm
plu
carrier
nonstandard
inconsist
therefor
differ
dbm
dose
deliv
tissu
site
differ
product
could
explain
variabl
respons
report
acarturk
holling
moreov
individu
dbm
lot
process
tissu
bank
may
possess
differ
osteoinduct
capac
capac
may
vari
among
differ
donor
biolog
activ
measur
osteoinduct
report
osteoinduct
index
oi
dbm
potenc
composit
regulatori
standard
enact
across
dbm
product
understand
control
differ
also
noteworthi
emphas
signific
shelf
life
carrier
stabil
dbm
composit
product
precis
control
condit
maintain
endogen
osteogen
protein
dbm
importantli
bmp
might
suscept
chemic
physic
degrad
variat
shelf
life
specif
carrier
may
may
affect
overal
activ
product
import
clinic
manufactur
issu
suffici
describ
control
dbm
consid
usa
fda
medic
devic
categor
head
human
cell
tissu
cellular
tissuebas
product
hctp
dbm
combin
synthet
carrier
becom
devic
implant
finit
increas
risk
infect
dbm
implant
medic
devic
must
provid
surgeon
certifi
steril
condit
fda
regul
steril
requir
devic
recent
guidanc
document
steril
k
medic
devic
dbm
provid
august
updat
k
steril
review
guidanc
guidanc
industri
fda
degre
steril
must
quantifi
provid
achiev
benchmark
set
point
industri
current
steril
assur
level
sal
requir
dbm
implant
set
sal
sal
nomenclatur
signifi
one
unit
one
million
devic
steril
would
fail
steril
test
implant
steril
method
categor
fda
either
tradit
nontradit
method
tradit
method
includ
dri
heat
steril
moist
heat
steril
ethylen
oxid
eto
fix
eto
chamber
gamma
electron
beam
radiat
liquid
chemic
steril
nontradit
method
defin
eto
use
fix
chamber
high
intens
light
chlorin
dioxid
ultraviolet
light
combin
vapor
ga
plasma
vapor
system
peroxid
peracet
acid
filtrat
manufactur
dbm
use
either
categori
provid
sal
threshold
met
tabl
list
method
appli
specif
product
evid
deminer
process
inactiv
certain
virus
tissu
bank
industri
process
prepar
dbm
product
reli
addit
step
ensur
dbm
free
bacteri
viral
contamin
steril
challeng
produc
dbmbase
product
steril
protocol
may
inactiv
attenu
bmp
dbm
confer
clinic
import
biolog
activ
termin
steril
dbm
report
ago
steril
method
result
impact
oi
recent
review
munt
cowork
prepar
rat
dbm
prepar
steril
use
differ
protocol
gamma
irradi
merthiol
glutaraldehyd
formaldehyd
ethylen
oxid
eto
glutaraldehyd
formaldehyd
eto
abolish
oi
merthiol
gamma
radiat
less
damag
oi
report
document
impact
steril
bmp
deriv
dbm
howev
unclear
whether
bmp
within
dbm
affect
differ
bmp
extract
dbm
steril
alon
lack
predict
tool
assess
impact
steril
protocol
oi
underscor
need
test
steril
method
particular
dbm
prepar
compar
differ
method
differ
dbm
prepar
tradit
certain
chemic
steril
method
alcohol
treatment
combin
solvent
deterg
yield
posit
result
method
still
use
suitabl
condit
also
identifi
radiationbas
method
radiat
dose
approxim
consid
suffici
steril
medic
implant
dose
within
rang
shown
degrad
dbm
also
capabl
inactiv
certain
virus
addit
steril
method
ebeam
hydrogen
peroxid
ga
plasma
success
use
contrast
satisfactori
method
eto
steril
remain
challeng
advantag
eto
steril
next
gamma
irradi
industri
standard
context
allograft
evid
eto
deactiv
virus
howev
studi
suggest
eto
dosedepend
declin
oi
other
show
littl
loss
activ
steril
controversi
may
hing
interact
physic
properti
dbm
prepar
process
variabl
associ
steril
cycl
exampl
studi
evalu
proinflammatori
respons
etosteril
dbm
vitro
suggest
small
particl
size
proinflamm
larger
particl
anoth
studi
humid
eto
exposur
process
modul
effect
eto
oi
reactiv
ga
eto
penetr
sorb
soft
porou
biomateri
like
dbm
degass
eto
commonli
use
porou
implant
might
poorli
control
compar
studi
remain
partial
unaddress
empir
studi
suggest
procedur
eto
steril
dbm
appear
combin
physic
process
step
includ
adequ
remov
lipid
time
temperatur
ethylen
oxid
exposur
well
thorough
process
remov
residu
eto
reactant
product
ethylen
glycol
ethylen
chlorohydrin
given
potenti
tradit
nontradit
steril
method
advers
impact
dbm
oi
mani
manufactur
resort
expens
option
asept
process
steril
achiev
asept
process
combin
manufactur
control
standard
oper
procedur
fda
provid
guidanc
document
septemb
entitl
guidanc
industri
steril
drug
product
produc
asept
processingcurr
good
manufactur
practic
help
manufactur
achiev
steril
asept
process
document
provid
inform
engin
human
control
use
ensur
steril
complianc
guidelin
ensur
steril
product
depend
adequ
manufactur
space
call
clean
room
suffici
air
qualiti
control
clean
room
must
higheffici
particul
air
hepa
filtrat
allow
entri
exit
staff
materi
without
introduct
infecti
agent
chemic
physic
condit
typic
steril
method
could
degrad
alter
biolog
deriv
substanc
avoid
asept
process
dbm
sever
dbm
manufactur
endors
cost
effect
asept
process
preserv
dbm
oi
dbm
produc
motiv
develop
dbm
longest
shelf
life
broadest
stabil
variou
storag
paramet
storag
distribut
system
streamlin
cost
effect
room
temperatur
storag
inexpens
mode
often
consequ
differ
dbm
produc
may
indic
respect
packet
insert
either
storag
room
temperatur
freez
dbm
product
recent
report
shed
light
potenti
mechanist
approach
storag
stabil
issu
dbm
author
use
vitro
alkalin
phosphatas
assay
ectop
bone
format
assay
nude
mice
determin
oi
either
hydrou
anhydr
dbm
prepar
prolong
exposur
temperatur
high
anhydr
dbm
substanti
resist
temperatur
relat
effect
oi
hydrou
version
dbm
decis
select
one
type
dbmcarrier
formul
anoth
may
determin
desir
clinic
target
exampl
clinic
situat
bone
void
inject
formul
would
favor
wherea
clinic
situat
may
includ
spine
fusion
procedur
flexibl
putti
may
better
advoc
howev
clinic
target
alon
may
insuffici
distinguish
one
product
formul
anoth
given
redund
among
sever
manufactur
dbm
product
line
consequ
necessari
compar
similar
dbm
product
preclin
model
determin
outcom
efficaci
clinic
handl
advantag
tabl
provid
comparison
differ
outcom
measur
method
anim
model
make
direct
comparison
among
studi
report
difficult
howev
trend
may
determin
notabl
differ
among
oi
across
dbm
prepar
differ
sourc
exist
seen
tabl
mention
differ
may
caus
dbm
process
donor
variabl
process
includ
steril
protocol
versu
asept
procur
well
quantiti
oi
potenc
per
unit
volum
dbm
found
within
carrier
consequ
sinc
process
steril
method
may
chang
time
use
collect
contemporari
compar
data
standard
model
especi
light
recent
k
clearanc
requir
mandat
control
valid
manufactur
process
unfortun
peerreview
report
routin
avail
nonbias
sourc
compani
often
provid
data
indic
superior
dbm
product
line
without
detail
scientif
valid
given
uniqu
sourc
human
bone
tissu
regul
dbm
fairli
uniqu
interest
three
major
aspect
dbm
medic
devic
suppli
chain
regul
donat
tissu
qualif
process
process
method
product
qualiti
approv
distribut
finish
product
specif
clinic
indic
first
instanc
uniform
anatom
gift
act
enact
revis
first
legisl
pass
law
defin
human
tissu
legal
donat
act
defin
step
donat
tissu
also
establish
principl
donat
tissu
may
sold
purchas
forego
exclud
payment
remov
process
dispos
preserv
qualiti
control
storag
transport
provis
law
particularli
import
dbm
provid
basic
framework
enabl
process
facil
invest
develop
cost
capit
equip
necessari
process
bone
dbm
provid
clinic
use
product
addit
govern
regul
promulg
food
drug
administr
fda
describ
dbm
sourc
procur
process
regul
activ
goal
limit
risk
diseas
transmiss
result
product
regul
mani
year
human
cell
tissu
cellular
tissu
base
product
hctp
regul
section
public
health
servic
ph
act
cfr
part
hctp
regul
process
facil
origin
permit
distribut
dbm
without
fda
premarket
approv
process
howev
earli
fda
clarifi
product
sole
regul
hctp
regul
appli
hctp
minim
manipul
hctp
intend
homolog
use
singl
level
interprocess
spinal
fusion
athym
rat
grafton
autograft
promot
fusion
rate
week
grafton
promot
respect
peterson
et
al
spinal
fusion
athym
rat
grafton
dbx
allomatrix
manual
palpat
week
fusion
grafton
fusion
dbx
acarturk
holling
critic
size
defect
athym
rat
manufactur
hctp
involv
combin
cell
tissu
compon
drug
devic
except
steril
preserv
storag
agent
addit
agent
rais
new
clinic
safeti
concern
respect
hctp
either
hctp
system
effect
depend
upon
metabol
activ
live
cell
primari
function
b
hctp
system
effect
depend
upon
metabol
activ
live
cell
primari
function
autolog
use
allogen
use
first
second
degre
rel
reproduct
use
importantli
fda
conclud
dbm
carrier
improv
use
handl
satisfi
provis
minim
manipul
issu
new
rule
dbm
prepar
becam
regul
fda
k
approv
process
k
approv
process
requir
medic
devic
manufactur
disclos
fda
manufactur
process
qualiti
control
method
anim
safeti
test
data
review
approv
prior
market
dbmbase
devic
k
approv
process
fda
also
determin
specif
label
claim
indic
distributor
commun
clinician
year
follow
rule
fda
sent
number
letter
processor
distributor
dbm
identifi
deadlin
submiss
k
applic
submit
k
applic
dbm
product
approv
receiv
fda
noncompli
produc
dbm
dbmcarrier
product
remov
market
final
comment
regulatori
issu
dbm
tissu
bank
industri
reli
peer
group
organ
maintain
standard
produc
american
associ
tissu
bank
aatb
american
societi
test
materi
astm
aatb
found
nonprofit
organ
facilit
qualiti
avail
allograft
cell
tissu
astm
centuryold
organ
provid
standard
test
method
mani
industri
intern
level
aatb
astm
provid
resourc
standard
procur
process
method
organ
highli
benefici
improv
qualiti
product
dbm
dbmcarrier
combin
origin
urist
definit
osteoconduct
threedimension
process
ingrowth
sprout
capillari
perivascular
tissu
osteoprogenitor
cell
recipi
bed
structur
implant
bone
graft
concept
detail
glowacki
mulliken
osteoconduct
occur
dead
bone
act
scaffold
ingrowth
vessel
follow
resorpt
implant
deposit
new
bone
deriv
edg
defect
process
slow
may
requir
year
unit
larg
segment
defect
origin
term
osteoinduct
also
urist
accur
today
process
differenti
pluripotenti
mesenchym
cell
osteoprogenitor
cell
ultim
osteoblast
form
bone
consequ
stimul
agent
bone
morphogenet
protein
urist
emphas
bone
matrix
morphogenet
substratum
solid
structur
support
morphogenesi
bone
matrix
substratum
play
permiss
support
role
morphogenesi
reddi
underscor
role
bone
matrix
also
anatom
field
deriv
allogen
transplant
deminer
bone
matrix
rat
transform
respond
fibroblast
chondroblast
osteoblast
transform
critic
depend
geometri
surfac
charg
author
emphasi
transform
site
ossicl
creat
transform
potenc
vari
wide
matric
differ
bone
rat
deminer
residu
tubular
bone
activ
matric
flat
bone
teach
bone
induct
principl
relat
deminer
bone
matrix
epoch
event
come
reddi
laboratori
usa
nidr
lab
sampath
reddi
test
hypothesi
portion
dissoci
extract
dbm
induct
factor
significantli
matrix
induct
reddi
succinctli
restat
almost
year
later
thu
would
appear
optim
osteogen
activ
collabor
author
emphasi
ad
solubl
extract
insolubl
collagen
substratum
glowacki
mulliken
refin
definit
osteoinduct
phenotyp
convers
connect
tissu
bone
appropri
stimulu
concept
impli
format
bone
demonstr
nonskelet
site
deminer
bone
dentin
osteoinduc
bank
donor
bone
divers
biolog
properti
consequ
donor
age
gender
effect
donor
age
gender
dbm
osteoinduct
access
variabl
explor
howev
limit
data
date
support
exclusionari
criterion
base
upon
either
one
potenti
agerel
factor
may
includ
metabol
compet
relev
balanc
bone
resorpt
deposit
investig
correl
properti
vitro
suggest
agerel
effect
exampl
groessnerschreib
et
al
report
osteoclast
recruit
assess
chick
chorioallento
membran
assay
decreas
human
dbm
prepar
donor
increas
age
howev
report
use
dbm
cohort
eight
donor
rang
age
consequ
studi
may
insuffici
power
aabo
colleagu
found
ectop
bone
format
dbm
differ
age
rat
seem
indic
modest
agerel
increas
osteoinduct
younger
vs
older
rat
donor
moreov
evalu
human
dbm
prepar
age
sex
stratifi
donor
indic
correl
donor
age
amount
extract
suggest
increas
age
decreas
bmp
content
review
similar
profil
observ
contrast
report
signific
correl
suggest
donor
age
given
level
nanogram
per
gram
level
cortic
bone
unclear
age
relat
effect
either
tgfare
clinic
meaning
asid
bmp
dbm
may
addit
endogen
growth
factor
consider
quantiti
insulinlik
growth
factor
igfi
transform
growth
factor
beta
tgfin
dbm
may
coregulatori
affect
bmp
noteworthi
igfi
tgfremain
rel
consist
age
howev
bae
cowork
report
variabl
growth
factor
content
across
commerci
dbm
prepar
noteworthi
howev
differenti
growth
factor
extract
effici
dbm
process
growth
factor
content
assay
might
contribut
suggest
dbm
product
content
differ
donorrecipi
gender
age
mention
variabl
could
affect
activ
dbm
howev
prepar
review
data
neither
valid
specul
donor
age
gender
affect
dbm
activ
recipi
age
influenc
respons
dbm
work
schwartz
colleagu
found
evid
gender
relat
differ
dbm
oi
moreov
zhang
group
report
oi
dbm
suggest
male
year
age
femal
year
age
better
oi
dbm
prepar
young
donor
contrast
lohmann
cowork
report
increas
donor
age
decreas
oi
prepar
dbm
donor
averag
age
year
found
averageag
cohort
higher
oi
older
group
addit
work
lohman
group
suggest
decreas
oi
increas
age
donor
data
group
valid
other
exampl
traianed
colleagu
determin
oi
human
dbm
prepar
male
femal
donor
data
indic
dbm
donor
old
oi
compar
younger
donor
absenc
convinc
data
contrari
work
lohman
group
duplic
suggest
age
affect
dbm
oi
definit
guidanc
tissu
processor
dbm
use
age
cutoff
donor
accept
gender
differenti
glowackimulliken
definit
osteoinduct
vida
supra
clearli
rais
bar
osteoinduct
valid
product
accept
definit
deriv
urist
reddi
underscor
vivo
environ
requir
test
osteoinduct
challeng
duplic
complex
biolog
vivo
environ
vitro
assay
howev
challeng
need
address
commerci
sector
sell
dbm
product
profound
compel
fiduciari
stimulu
develop
vitro
correl
vivo
environ
reliabl
valid
dbm
biolog
activ
accur
verifi
osteoinduct
simpl
rational
corpor
sector
vitro
assay
quicker
less
expens
vivo
assay
number
skill
worker
tri
develop
vitro
paradigm
select
bone
cell
line
identifi
marqui
bone
marker
may
use
verifi
biolog
activ
dbm
carn
cowork
report
cell
line
effect
verifi
osteoinduct
conclud
studi
underscor
frustrat
inher
develop
reliabl
rapid
assay
bone
induct
abil
either
cell
cultur
vivo
contrast
adkisson
colleagu
report
sao
human
osteosarcoma
cell
prolifer
respons
dbm
transform
cancer
cell
cultur
prolifer
result
directli
support
respons
correl
vivo
osteoinduct
nonetheless
bold
conclus
glowacki
basic
bone
biolog
expert
evalu
current
state
knowledg
lead
fact
conclud
perform
differ
lot
deminer
bone
allograft
vivo
vitro
test
system
use
measur
clinic
perform
may
possibl
adopt
osteoinduct
standard
releasetomarket
follow
clinic
monitor
research
sever
fundament
criteria
must
fulfil
success
biolog
osteoinduct
assay
assay
must
standard
reproduc
within
laboratori
among
differ
laboratori
outcom
must
accur
quantifi
within
batch
dbm
across
batch
within
laboratori
among
laboratori
moreov
biolog
assay
use
clinic
predictor
perform
must
correl
accur
precis
clinic
outcom
standard
vivo
biolog
assay
bone
induct
mous
hamstr
implant
describ
urist
numer
variat
follow
includ
subcutan
pectorali
major
implant
procedur
assay
dbm
oi
biolog
activ
involv
implant
known
weight
eg
dbm
rodent
muscl
load
critic
stimul
new
bone
dbm
implant
perform
absenc
control
mechan
load
approxim
rodent
euthan
explant
muscl
mass
radiograph
tissu
process
histolog
assess
radiograph
examin
radiopac
histolog
tissu
assess
includ
subject
grade
bone
format
among
number
random
histolog
section
certain
magnif
use
stain
choic
laboratori
eg
goldner
trichrom
arbitrari
valu
ie
numer
grade
given
examin
histolog
slide
base
bone
observ
without
clear
standard
endpoint
bone
architectur
defin
field
may
littl
relev
numer
score
among
differ
bone
bank
laboratori
sometim
differ
score
within
laboratori
therefor
standard
procedur
need
adopt
bone
bank
grade
biolog
eg
osteoinduct
outcom
dbm
vivo
assay
standard
grade
necessari
ensur
suitabl
qualiti
control
within
bone
bank
laboratori
among
differ
bone
bank
laboratori
clinic
trend
wit
increas
passion
biolog
research
stimul
innat
capac
bone
regener
rapid
predict
manner
irrespect
natur
bone
malform
defect
fractur
logic
use
dbm
inher
bmp
growth
factor
modul
bone
repair
howev
date
impress
implant
result
still
come
dbm
conjunct
autogen
bone
graft
combin
provid
scaffold
viabl
cell
proper
signal
effect
recapitul
tissu
regener
mention
deminer
bone
product
exist
mani
form
powder
putti
flexibl
sheet
gel
tabl
desir
clinic
outcom
dictat
form
use
burwel
first
suggest
osteoinduct
potenti
alloimpl
could
maxim
combin
autogen
marrow
pike
boyn
later
use
surfacedecalcifi
allogen
bone
bone
graft
tray
retain
autogen
cancel
marrow
combin
autogen
bone
marrow
deminer
product
known
provid
greater
osteogen
potenti
either
bone
marrow
deminer
matrix
alon
deminer
bone
product
use
dentistri
primarili
periodont
regener
reconstruct
jaw
dental
implant
placement
periodont
regener
challeng
graft
perform
infect
site
often
complic
patient
smoke
diabet
furthermor
graft
attempt
reconstruct
bone
also
cementum
periodont
ligament
classic
approach
periodont
regener
use
bone
graft
howev
deminer
product
began
attract
attent
periodont
regener
earli
bower
colleagu
show
averag
new
attach
format
compar
attach
periodont
defect
debrid
current
three
question
domin
dental
field
dbm
deminer
bone
product
osteoinduct
deminer
product
significantli
better
periodont
regener
product
eg
miner
xenograft
hydroxyapatit
polym
bioactiv
ceram
growth
factor
biomimet
therapeut
inc
longterm
fate
periodont
defect
graft
deminer
bone
recent
data
sever
clinic
studi
valid
superior
rhpdgfcontain
product
fdaapprov
periodont
regener
biomimet
therapeut
inc
usa
either
dbm
dfdba
craniofaci
applic
deminer
bone
product
limit
current
product
design
contemporari
deminer
product
design
bone
filler
bone
defect
wall
defect
bound
exist
intact
bone
craniofaci
applic
challeng
requir
structur
support
protect
dura
essenti
element
success
bone
substitut
materi
earli
mulliken
et
al
report
deminer
bone
powder
cranial
reconstruct
sinc
sever
group
use
deminer
bone
prepar
cranial
reconstruct
reconstruct
nasomaxillari
cleft
defect
ousterhout
place
deminer
implant
facial
defect
lefort
osteotomi
found
deminer
product
augment
facial
contour
result
consider
resorpt
deminer
bone
defect
gener
result
satisfactori
osteogenesi
applic
deminer
bone
product
hand
surgeri
report
limit
frequenc
deminer
bone
product
success
use
reconstruct
phalang
metacarp
defect
follow
enchondroma
congenit
hand
surgeri
similarli
deminer
bone
product
foot
surgeri
infrequ
report
weinraub
cheung
use
allogen
bone
either
without
deminer
bone
sever
procedur
includ
arthrodesi
segment
lengthen
treatment
nonunion
michelson
curl
evalu
deminer
autogen
bone
subtalar
fusion
tripl
arthrodesi
patient
year
period
conclud
deminer
bone
graft
aid
arthrodesi
least
well
iliac
crest
bone
graft
without
increas
blood
loss
cost
postop
pain
associ
iliac
crest
bone
harvest
autogen
bone
graft
materi
choic
orthopaed
scienc
howev
deminer
bone
garner
attent
repair
cyst
fractur
segment
bone
defect
nonunion
tiedman
group
use
deminer
bone
alon
composit
graft
autogen
bone
marrow
orthopaed
applic
conclud
dbm
marrow
composit
graft
suitabl
altern
autogen
iliac
crest
bone
graft
clinic
situat
bone
defect
children
comminut
fractur
associ
bone
loss
nonunit
fractur
augment
arthodesi
one
prospect
studi
use
deminer
bone
product
orthopaed
geesink
et
al
compar
osteogen
stryker
biomed
inc
also
known
grafton
gel
fibular
defect
earli
time
point
superior
union
howev
differ
bone
miner
densiti
score
dbm
grafton
gel
although
controversi
control
studi
anecdot
report
suggest
bone
graft
substitut
includ
deminer
bone
matrix
may
result
improv
treatment
outcom
patient
fractur
distal
radiu
spinal
fusion
use
autogen
bone
goldstandard
treatment
mani
disord
spine
sassard
et
al
cammisa
cowork
evalu
miner
effici
bone
mass
patient
posterolater
lumbar
spinal
fusion
either
autogen
bone
alon
composit
grafton
dbm
fusion
rate
miner
effici
similar
group
simpson
et
al
analyz
fusion
result
allograftgrafton
composit
versu
autograft
prospect
seri
patient
undergo
anterior
cervic
fusion
surgeri
cervic
disc
diseas
conclud
autograft
demonstr
less
graft
collaps
pseudoarthrosi
compar
allograftgrafton
composit
group
overal
differ
studi
outcom
preclin
clinic
report
like
reflect
differ
among
anim
model
preclin
dbm
formul
outcom
measur
knowledg
gain
decad
dbm
product
use
led
gener
guidelin
concern
clinic
applic
first
use
deminer
bone
conjunct
autogen
bone
demonstr
synergist
osteogen
respons
second
deminer
bone
product
bone
defect
provid
qualit
quantit
bone
heal
result
depend
volumetr
characterist
defect
osseou
defect
two
wall
eg
segment
continu
defect
would
expect
less
predict
osteogenesi
defect
one
wall
third
deminer
bone
product
advis
augment
facial
cranial
contour
deficit
due
tendenc
resorpt
fourth
consider
variabl
tissu
bank
process
deminer
product
well
lottolot
variabl
composit
oi
confus
concern
still
dbm
use
though
dbm
success
use
alongsid
allograft
bone
use
alon
applic
undergo
high
compress
load
contraind
lead
greater
graft
collaps
inher
absenc
structur
rigid
clinic
demand
bone
void
filler
obviat
need
harvest
autograft
prompt
develop
synthet
biolog
autograft
substitut
among
clinic
success
filler
dbm
dbm
osteoconduct
osteoinduct
rel
easi
use
clinic
especi
carrier
formul
divers
offer
moreov
dbm
extend
volum
autograft
matur
dbm
bone
biolog
tool
understand
bmp
growth
factor
biolog
pioneer
bone
regen
recombin
therapeut
led
tissu
bank
protocol
standard
donor
procur
process
steril
dbm
initi
nonfda
regul
tissuederiv
product
howev
clinic
appeal
expand
innov
dbm
formul
carrier
design
develop
increas
clinic
util
consequ
manipul
clinic
use
fda
regul
dbm
k
medic
devic
therefor
dbm
product
must
satisfi
regulatori
guidelin
ensur
biocompat
manufactur
valid
shelf
life
osteoinduct
potenti
latter
biolog
properti
garner
interest
clinician
bone
applic
dbm
intrins
osteoinduct
mechan
releas
endogen
bmp
growth
factor
diffus
matrix
biodegrad
compel
question
regard
dbm
futur
util
regard
remain
answer
standard
dbm
oi
across
bone
bank
industri
improv
process
qualiti
control
assist
standard
dbm
threshold
carrier
formul
must
fulfil
ensur
optimum
oi
import
concern
dbm
industri
lack
reliabl
correl
metric
oi
potenti
assess
vitro
vivo
model
signific
human
clinic
efficaci
compar
preclin
perform
pursu
anim
model
may
impract
address
human
clinic
set
despit
lack
compar
clinic
perform
data
clinician
benefit
emerg
competit
among
manufactur
provid
improv
dbm
formul
rigor
test
valid
oi
outstand
issu
regard
dbm
clinic
use
lack
current
support
studi
date
includ
impact
dbm
oi
recipi
patient
osteoporot
bisphosphon
activ
nsaid
pharmacolog
patient
smoke
diabet
uniqu
region
physiolog
differ
across
appendicular
axial
craniofaci
skeleton
may
requir
design
dbm
composit
format
improv
clinic
outcom
dbm
composit
design
loadbear
calibr
remodel
bone
regener
new
work
must
done
address
clinic
relev
issu
affect
dbm
efficaci
overal
bone
graft
substitut
market
grow
rate
per
year
dbm
segment
expand
modest
us
market
orthoped
biomateri
millenium
research
group
septemb
consequ
given
commerci
distract
new
biotechnolog
might
one
day
supplant
dbm
may
academ
institut
rather
within
corpor
bone
bank
organ
address
import
unansw
dbm
scientif
therapeut
question
concern
issu
relev
futur
clinic
opportun
dbm
oi
modul
standard
product
valid
seem
like
nearterm
need
howev
despit
modest
product
growth
rate
anticip
dbm
surgic
marketplac
dbm
current
highli
valu
therapeut
devic
surgeon
continu
remain
import
especi
light
emerg
market
current
health
care
system
bare
substanti
cost
associ
recombin
growth
factor
deliveri
see
contribut
theme
issu
protein
therapeut
bone
consequ
research
effort
dbm
must
sustain
expand
clinic
applic
produc
valid
util
demonstr
new
option
opportun
enhanc
clinic
outcom
bone
repair
